Merrell Dow Pharmaceuticals Inc. v. Thompson

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 11, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ACAD, Merrell Dow Pharmaceuticals Inc. v. Thompson, Pharmaceutical industry, Cryptocurrency

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time.
  • The conference will be held virtually.
  • A live webcast of the presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

Retrieved on: 
Monday, March 20, 2023
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, Hypertriglyceridemia, Triglyceride, NDA, Fast Track, Merrell Dow Pharmaceuticals Inc. v. Thompson, Trial of the century, Orphan drug, PALISADE, Genetic disorder, Arrowhead Pharmaceuticals, MD, Patient, European, APOC3, RNA interference, FCS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
  • ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union.
  • Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need.
  • This designation makes Arrowhead eligible for multiple potential benefits including more frequent interactions with FDA, eligibility for accelerated approval and priority review, and rolling review of the new drug application (NDA).

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Retrieved on: 
Friday, February 24, 2023
Biotechnology, General Health, FDA, Health, Pharmaceutical, Merrell Dow Pharmaceuticals Inc. v. Thompson, Conference, Broadcasting, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.
  • Oppenheimer 33rd Annual Virtual Healthcare Conference being held March 13 – 15, 2023.
  • Presentation time Tuesday, March 14, from 9:20 – 9:50 AM ET.
  • To participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com .

Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection

Retrieved on: 
Thursday, February 9, 2023
FDA, Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Nexus, Food, AP, Food and Drug Administration, Merrell Dow Pharmaceuticals Inc. v. Thompson, US Foods, IV, Patient, Tirofiban, Injection, Pharmaceutical industry

Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags.

Key Points: 
  • Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags.
  • Tentative approval has been granted for concentrations of 12.5mg/250mL single-dose IV-bags.
  • “Being granted this approval is a milestone for us, but also for patients who want more transparency in the healthcare they receive.
  • We eagerly anticipate bringing it to market in the coming months.”
    Nexus Pharmaceuticals’ Tirofiban Hydrochloride for Injection will be available in cartons of sole single-dose IV bags.

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Retrieved on: 
Tuesday, February 7, 2023
Biotechnology, General Health, Pharmaceutical, Health, U.S.–Canada Team Tournament (Go), Merrell Dow Pharmaceuticals Inc. v. Thompson, Video game, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open.
  • Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.
  • The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com .
  • A replay of the audio webcast will be available on Aurinia’s website.

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

Retrieved on: 
Wednesday, January 25, 2023
Cardiology, Biotechnology, FDA, Health, Public Relations, Investor Relations, Pharmaceutical, Oncology, Communications, Infectious Diseases, Genetics, Clinical Trials, PIN, Arrowhead Pharmaceuticals, Merrell Dow Pharmaceuticals Inc. v. Thompson, Webcast, Cryptocurrency

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Retrieved on: 
Wednesday, December 21, 2022
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Merrell Dow Pharmaceuticals Inc. v. Thompson, ACAD, Conference, Pharmaceutical industry, Self storage

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.
  • A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets due to potential presence of N-Nitroso-Quinapril Impurity

Retrieved on: 
Wednesday, December 21, 2022
Online, Lupin Limited, EST, Patient, Food, Knowledge, Supermarket, FDA, Completeness, Prescription, Multimedia, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, Merrell Dow Pharmaceuticals Inc. v. Thompson, Dietary supplement, Pharmaceutical industry

Patients taking, Quinapril Tablets USP, 20mg, and 40mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.

Key Points: 
  • Patients taking, Quinapril Tablets USP, 20mg, and 40mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.
  • Wholesalers, distributors and retailers that have Quinapril Tablets USP, 20mg, and 40mg that are being recalled should discontinue distribution of the recalled product lots immediately.
  • Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (877) 538-8445 Monday – Friday 09:00 am to 05:00 pm EST.
  • Lupin Pharmaceuticals, Inc. is the U.S. based wholly-owned subsidiary of Lupin Limited and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions.

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results

Retrieved on: 
Monday, November 14, 2022
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Infectious Diseases, Clinical Trials, RNA interference, PIN, Gene silencing, News, Merrell Dow Pharmaceuticals Inc. v. Thompson, Safety, Security (finance), Arrowhead Pharmaceuticals, Annual report, Therapy, RNA, COVID-19, Arrowhead, Gene, Webcast, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m.
  • ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022.
  • The forward-looking statements in the webcast speak only as of the original date of the webcast.
  • We assume no obligation to update or revise forward-looking statements contained in the webcast to reflect new events or circumstances.

AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

Retrieved on: 
Thursday, November 3, 2022
Merrell Dow Pharmaceuticals Inc. v. Thompson, Syringe, Sufentanil, News, COVID-19, Ephedrine, Adult, Acute respiratory distress syndrome, Phenylephrine, SST, Pain, Patient, PCA, Company, ID, Webcast, Multimedia, Pharmaceutical industry, Broadcasting

HAYWARD, Calif., Nov. 3, 2022 /PRNewswire/ --AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close onMonday, November 14, 2022.

Key Points: 
  • HAYWARD, Calif., Nov. 3, 2022 /PRNewswire/ --AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close onMonday, November 14, 2022.
  • Thereafter, AcelRx management will host a live webcast and conference call at4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time onNovember 14, 2022,to discuss the financial results and provide an update on the Company's business.
  • The webcast can be accessed by visiting the "Investors" section of the Company's website at www.acelrx.com and clicking on the webcast link within the News & Events/Upcoming Events section.
  • The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.